Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 51.28% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 2.94% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -70.54% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 4.50% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -7.75% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 66.11% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -17.90% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | -38.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66.11% |
| Dec 31, 2025 | 19.98% |
| Sep 30, 2025 | 45.15% |
| Jun 30, 2025 | 102.96% |
| Mar 31, 2025 | -17.17% |
| Dec 31, 2024 | 152.63% |
| Sep 30, 2024 | 79.35% |
| Jun 30, 2024 | 15.40% |
| Mar 31, 2024 | 10.58% |
| Dec 31, 2023 | -24.84% |
| Sep 30, 2023 | 51.00% |
| Jun 30, 2023 | 6.26% |
| Mar 31, 2023 | -59.37% |
| Dec 31, 2022 | 37.82% |
| Sep 30, 2022 | 8.39% |
| Jun 30, 2022 | -32.56% |
| Mar 31, 2022 | 28.79% |
| Dec 31, 2021 | -33.68% |
| Sep 30, 2021 | -23.76% |
| Jun 30, 2021 | 109.19% |